Pyr3是瞬时受体电位经典通道3（TRPC3）的一种强效、选择性抑制剂，对TRPC3介导的钙离子内流的IC50为700nM。
Cas No.:1160514-60-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Pyr3 is a potent and selective inhibitor of transient receptor potential canonical channel 3 (TRPC3), with an IC50 of 700nM for TRPC3-mediated Ca2+ influx [1]. Pyr3 can reduce the secretion level of MMP9 in cells and inhibit the phosphorylation of signal transducer and activator of transcription (STAT) 5[2]. Pyr3 has been widely used to inhibit the proliferation and migration of melanoma, as well as to regulate tumor growth and metastasis[3].
In vitro, Pyr3 treatment for 48 hours significantly inhibited the proliferation of A549 cells, HCT-116 cells, and PC3 cells, with IC50 values of 15.4, 7.9, and 2.3μg/ml, respectively[4]. Treatment with 10μM Pyr3 for 24 hours significantly inhibited the viability of T24 cells, induced cell cycle arrest, and decreased the expression levels of p-PKCα, PKCα and PP2A[5]. Treatment with 1.0μM Pyr3 for 8 hours significantly induced apoptosis in MDA-MB-231 cells, accompanied by cell contraction, cell membrane blebbing, mitochondrial fragmentation and nuclear condensation[6].
In vivo, Pyr3 treatment via intraperitoneal injection at a dose of 20mg/kg/day for seven consecutive days significantly inhibited the growth of glioma tumors in the xenograft mouse model[7]. Five minutes before reperfusion, 10mg/kg of Pyr3 was administered via the right jugular vein to the mice, which significantly reduced the infarcted area of the left ventricle in the mice, and decreased the rate of myocardial cell apoptosis and inflammatory response[8].
References:
[1] Kiyonaka S, Kato K, Nishida M, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound[J]. Proceedings of the National Academy of Sciences, 2009, 106(13): 5400-5405.
[2] Oda K, Umemura M, Katsumata M, et al. Transient receptor potential cation channel 3 (TRPC3) regulates tumor proliferation and migration of BRAF wild type human malignant melanoma[J]. Cancer Research, 2015, 75(15_Supplement): 4371-4371.
[3] Umemura M, Baljinnyam E, De Lorenzo M S, et al. Role of store-operated Ca2+ entry in proliferation and cell cycle in melanoma[J]. Cancer Research, 2012, 72(8_Supplement): 1864-1864.
[4] Kıyan H T, Üvez A, Erkisa M, et al. A Comparative Study on In vitro Anti-cancer and In vivo Anti-angiogenic Effects of TRPC Blockers Pyr-3 and SKF-96365[J]. Letters in Drug Design & Discovery, 2023, 20(7): 957-964.
[5] Ting H K, Dou Y C, Lin Y H, et al. Pyr3 inhibits cell viability and PKCα activity to suppress migration in human bladder cancer cells[J]. European Journal of Pharmacology, 2025, 988: 177235.
[6] Wang Y, Qi Y X, Qi Z, et al. TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway[J]. Cancers, 2019, 11(4): 558.
[7] Chang H H, Cheng Y C, Tsai W C, et al. Pyr3 induces apoptosis and inhibits migration in human glioblastoma cells[J]. Cellular Physiology and Biochemistry, 2018, 48(4): 1694-1702.
[8] Lu M, Fang X, Shi D, et al. A selective TRPC3 inhibitor Pyr3 attenuates myocardial ischemia/reperfusion injury in mice[J]. Current Medical Science, 2020, 40(6): 1107-1113.
Pyr3是瞬时受体电位经典通道3（TRPC3）的一种强效、选择性抑制剂，对TRPC3介导的钙离子内流的IC50为700nM[1]。Pyr3能降低细胞中MMP9的分泌水平，并抑制信号转导和转录激活因子5的磷酸化[2]。Pyr3已广泛用于抑制黑色素瘤的增殖和迁移，以及调节肿瘤的生长和转移[3]。
在体外，Pyr3处理48小时显著抑制了A549细胞、HCT-116细胞和PC3细胞的增殖，IC50值分别为15.4μg/ml、7.9μg/ml和2.3μg/ml[4]。用10μM的Pyr3处理24小时显著抑制了T24细胞的活力，诱导了细胞周期阻滞，并降低了p-PKCα、PKCα和PP2A的表达水平[5]。用1.0μM的Pyr3处理8小时显著诱导了MDA-MB-231细胞的凋亡，伴随细胞收缩、细胞膜起泡、线粒体碎片化和核固缩[6]。
在体内，以20mg/kg/day的剂量连续七天腹腔注射Pyr3显著抑制了异种移植小鼠模型中胶质瘤的生长[7]。再灌注前五分钟通过右颈静脉给小鼠注射10mg/kg的Pyr3，显著减小了小鼠左心室的梗死面积，并降低了心肌细胞凋亡率和炎症反应 [8]。
| Cell experiment [1]: | |
Cell lines | A549 cells |
Preparation Method | A549 cells were grown in RPMI 1640 medium supplemented with penicillin G (100U/ml), streptomycin (100μg/ml), L-glutamine, and 10% fetal bovine serum in a humidified incubator at 37°C and 5% CO2. Cells were seeded at a density of 5×103 cells/well in 96 well plates and treated with different concentrations of Pyr3 (0.62, 1.25, 2.5, 5, 10, 20, and 40µg/ml) for 48h. Then, cells were in situ fixed with 50μl of 50% (w/v) trichloroacetic acid at 4°C for 1h. At the end of fixation, wells were washed 5 times with deionized water and allowed air dry at room temperature for 50μl of 0.4% SRB solution was added into each well and incubated at room temperature for 30min. Then, plates were washed with 1% acetic acid to eliminate non-specific bindings and un bounded dye. The bounded SRB dye was dissolved by adding 150μl 10mM Tris base per each well. Measurements were carried out at 564nm. |
Reaction Conditions | 0.62, 1.25, 2.5, 5, 10, 20, and 40µg/ml; 48h |
Applications | Pyr3 treatment notably decreased the cell viability of A549 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | BALB/cAnN.Cg-Foxn1nu/CrlNarl nude mice |
Preparation Method | BALB/cAnN.Cg-Foxn1nu/CrlNarl nude mice (20-25g) were anesthetized with an oxygen/isoflurane mixture gas. Subsequently, 1×105 LN229-Luc2 cells were implanted into the right cerebral hemisphere of the mice. Four days after implantation, the mice were randomly divided into four groups and received treatment with a vector control, or Pyr3. Pyr3 was dissolved in 10% Tween 80 and administered intraperitoneally at a dose of 20mg/kg/day for 7 days. Twelve days later, the mice were euthanized with carbon dioxide; the brain tissues were removed, fixed with formalin, embedded in paraffin, and cut into consecutive sections. The bioluminescence intensity of the implanted tumors was monitored using the non-invasive in vivo imaging system (IVIS) three times a week. The weight of the mice was measured three times a week. |
Dosage form | 20mg/kg/day for 7 days; i.p. |
Applications | Pyr3 treatment inhibited glioma tumor growth in the xenograft orthotopic model without affecting body weight. |
References: | |
| Cas No. | 1160514-60-2 | SDF | |
| 化学名 | ethyl 1-(4-(2,3,3-trichloroacrylamido)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate | ||
| Canonical SMILES | Cl/C(C(NC1=CC=C(C=C1)N2N=CC(C(OCC)=O)=C2C(F)(F)F)=O)=C(Cl)\Cl | ||
| 分子式 | C16H11Cl3F3N3O3 | 分子量 | 456.63 |
| 溶解度 | DMF: 50 mg/ml,DMSO: 20 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.19 mL | 10.9498 mL | 21.8996 mL |
| 5 mM | 438 μL | 2.19 mL | 4.3799 mL |
| 10 mM | 219 μL | 1.095 mL | 2.19 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet